Antimicrobial resistance companies develop diagnostics, therapeutics and technologies to address infections that no longer respond effectively to existing medicines. Their work supports faster pathogen identification, improved treatment decisions and the development of new approaches to infection control.
This category includes companies working on:
Browse 53 UK antimicrobial resistance companies below.
AI-powered rapid pathogen ID and antibiotic susceptibility from blood
Vivid Dx is a University of Oxford spin-out developing a culture-free diagnostics platform for rapid pathogen identification and antimicrobial susceptibility testing directly from blood samples. The system combines Raman spectroscopy, microfluidics, and deep learning to deliver species-level pathogen identification in…
XF-73 antimicrobial advancing towards Phase 3 infection prevention
AMR Bio is a clinical-stage biotechnology company developing the XF-73 antimicrobial platform for preventing hospital-acquired infections. Its lead nasal formulation aims to reduce Staphylococcus aureus carriage before surgery. Following Phase 2b clinical testing, the programme is preparing for Phase 3 development.…
Food and gut health bioscience research on Norwich Research Park
Quadram Institute Bioscience is a BBSRC-funded independent research organisation focused on the interactions between food, gut microbiota, and human health. Operating within the Quadram Institute, a partnership with the University of East Anglia, Norfolk and Norwich University Hospitals, and BBSRC, it conducts…
Molecular diagnostic PCR, dPCR and NGS kits for clinical laboratories
TRUPCR Europe develops and supplies molecular diagnostic kits and reagents for clinical and research laboratories. Its portfolio includes real-time PCR, digital PCR and next-generation sequencing assays for oncology, haematological malignancies, infectious diseases and antimicrobial resistance. Products also include…
Novel antibiotic-sparing therapeutics for chronic wound care
ONYA Therapeutics is a biotechnology company developing novel pharmaceutical treatments for acute and chronic wounds. The company's pipeline centres on a patented controlled-release drug delivery technology designed to manage wound exudate and reduce reliance on antibiotics, addressing antimicrobial resistance in…
Immunotherapeutics targeting drug-resistant bacterial infections
Centauri Therapeutics is a clinical-stage immunotherapy company developing treatments for life-threatening infectious diseases using its proprietary platform. The technology uses synthetic bifunctional molecules that recruit and redirect naturally occurring anti-glycan antibodies to target pathogens, engaging both…
DNA topoisomerase enzymes and substrates for drug discovery
Inspiralis is a John Innes Centre spinout supplying DNA-modifying enzymes, substrates and assay kits to pharmaceutical and academic researchers. Its product range centres on topoisomerases, enzymes that regulate DNA topology and represent validated targets for antibiotic and anticancer drug development. Alongside its…
Inorganic nanoscale immune modulators for infection, cancer and autoimmunity
Iuvantium is a biotechnology company developing therapeutics and vaccines based on inorganic nanoscale materials that modulate the immune system. The company uses tailored inorganic probes to study how the immune system responds, builds a computational model of immune behaviour, and designs programmable immune…
Rapid point-of-care bacterial diagnostics and antibiotic susceptibility testing
FluoretiQ Limited is a diagnostics company developing rapid point-of-care tools for bacterial identification and antibiotic susceptibility testing to support antimicrobial stewardship. Its platform uses functionalised nanoparticles and machine learning to identify and quantify bacterial pathogens from clinical samples…
Rapid antimicrobial susceptibility testing platform for urinary infections
Astratus is an instruments company developing a rapid antimicrobial susceptibility testing platform for clinical microbiology. Its microcapillary cassette and reader system delivers digital susceptibility results directly from urine samples in under six hours, compared to the two to three days required by standard…
Precision bacteriocin antibiotics targeting drug-resistant Gram-negative pathogens
Glox Therapeutics is a Scottish biotech developing a pipeline of engineered protein bacteriocins as precision antibiotics against drug-resistant Gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa. Spun out of the Universities of Glasgow and Oxford in 2023, the company…
Multiplex PCR pathogen detection kits for infectious disease diagnostics
Genetic Signatures is a molecular diagnostics company supplying multiplex real-time PCR detection kits for infectious disease testing in hospital and pathology laboratories. Its proprietary technology simplifies genetic sequences to improve multiplex efficiency and increase resistance to pathogen mutation,…
Rapid bacterial viability detection using optical electrophysiology
Cytecom is a biotechnology company developing instruments for the rapid detection and quantification of live bacteria. The company's platform combines fluorescence microscopy with electrical stimulation to assess bacterial membrane potential, distinguishing viable from non-viable cells within minutes. The technology…
Culturing microbial dark matter to discover novel antimicrobials and bioactives
Bactobio is a biotechnology company using synthetic biology, next-generation sequencing, and machine learning to culture the vast majority of environmental microbes that have previously been unculturable. Access to this largely unexplored bioresource enables systematic discovery of novel antimicrobial compounds and…
Semiconductor sequencing platform for point-of-need diagnostics
DNA Electronics is a diagnostics company developing a semiconductor-based DNA sequencing platform for rapid, direct-from-specimen genomic analysis at the point of need. Its proprietary system integrates sample preparation and next-generation sequencing on a microchip, enabling clinical identification of bloodstream…
AI drug discovery platform developing novel biologics for cancer and AMR
AMPLY Discovery is a biotechnology company developing an AI-driven drug discovery platform that combines machine learning, next-generation sequencing, and synthetic biology to identify novel biologic drug candidates from natural biological diversity. The platform digitises biological molecules, identifies treatment…
Plasmonic PCR diagnostics for rapid infectious disease detection
RapidX Bio is a biotechnology company developing point-of-care molecular diagnostics for infectious diseases. Its plasmonic PCR technology uses light-responsive gold nanorods to accelerate nucleic acid amplification and reduce sample preparation requirements. The company is developing portable tests to identify…
AI-driven tRNA synthetase platform for novel small molecule therapeutics
Oxford Drug Design is an Oxford biotech developing small molecule therapeutics using an integrated platform combining aminoacyl-tRNA synthetase biology with proprietary generative AI and machine learning. The platform provides structural biology knowledge, crystallographic data, and novel chemotypes targeting tRNA…
Infectious disease research platforms and industry-academic partnerships
iiCON (Infection Innovation Consortium) is a Liverpool-led research partnership accelerating the discovery and development of infectious disease interventions. Led by Liverpool School of Tropical Medicine, it connects industry, academia and the NHS through specialist platforms covering antimicrobial discovery,…
Microbiology and biofilm testing contract research organisation
5D Health Protection Group is a UK-based contract research and microbiology testing organisation providing antimicrobial, biofilm and infection control research services to healthcare, medical device and industrial clients. The company offers accredited laboratory testing, product evaluation and outsourced R&D support…